Cell reports

How GluN2D-targeting drugs and ketamine influence inhibitory signals, long-term brain strengthening, and motivation

Updated

Abstract

GluN2D-NMDARs at presynaptic terminals of hippocampal parvalbumin-interneurons are activated by changes in basal glutamate to control GABA release.

  • GABAergic interneurons play a critical role in balancing brain activity by suppressing excessive signaling.
  • The specific composition of NMDAR subunits in interneurons is largely unknown, despite their importance.
  • GluN2D-NMDARs contain presynaptic targeting information within their intracellular C-terminal.
  • Inhibition of GABA release by certain modulators is absent in mice lacking GluN2D in parvalbumin-interneurons.
  • The selective inhibitor NAB14 mimics ketamine's effects on long-term potentiation and reward motivation in a depression model without its negative side effects.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Declaration of interests S.F.T. is a medical advisory board member for CureGRIN Foundation and GRIN2B Foundation, on the scientific advisory boards for Eumentis Therapeutics and Neurocrine, a consultant for GRIN Therapeutics and Seyltx, and co-founder of NeurOp, Inc. and Sensa Neuroscience. H.Y., S.F.T. are PIs for research grants to Emory from GRIN Therapeutics. R.E.P., S.J.M. are consultants for GRIN Therapeutics. D.C.L., S.F.T. are on the Board of Directors for NeurOp, Inc. D.C.L., N.S.A., S.J.M., H.Y., S.F.T. are co-inventors on Emory-owned IP.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free